Molecular classification of estrogen receptor-positive/luminal breast cancers.
about
ERRβ signalling through FST and BCAS2 inhibits cellular proliferation in breast cancer cells.Survival Analysis Based on Clinicopathological Data from a Single Institution: Chemotherapy Intensity Would Be Enhanced in Patients with Positive Hormone Receptors and Positive HER2 in China Who Cannot Afford the Target TherapyBiological subtypes of breast cancer: Prognostic and therapeutic implications.Evaluation of Ki67 expression across distinct categories of breast cancer specimens: a population-based study of matched surgical specimens, core needle biopsies and tissue microarraysThe maximum standardized uptake value of 18 F-FDG PET scan to determine prognosis of hormone-receptor positive metastatic breast cancerQuantum dots-based quantitative and in situ multiple imaging on ki67 and cytokeratin to improve ki67 assessment in breast cancer.Stromal genes add prognostic information to proliferation and histoclinical markers: a basis for the next generation of breast cancer gene signatures.Cancer stem cell-driven efficacy of trastuzumab (Herceptin): towards a reclassification of clinically HER2-positive breast carcinomas.Oxidative stress specifically downregulates survivin to promote breast tumour formationBreast cancer subtype intertumor heterogeneity: MRI-based features predict results of a genomic assay.STAT signaling in different breast cancer sub-types.Are breast cancer molecular classes predictive of survival in patients with long follow-up?Overexpression of TMPRSS4 promotes tumor proliferation and aggressiveness in breast cancerChemotherapy regimens in early breast cancer: major controversies and future outlook.Biomarkers of drugs targeting HER-family signalling in cancer.MCM2: An alternative to Ki-67 for measuring breast cancer cell proliferation.Breast cancer prognosis predicted by nuclear receptor-coregulator networks.Magnetic resonance metabolic profiling of estrogen receptor-positive breast cancer: correlation with currently used molecular markers.Ki67 targeted strategies for cancer therapy.Heavy metals effect on breast cancer progression.The use of automated Ki67 analysis to predict Oncotype DX risk-of-recurrence categories in early-stage breast cancer.Phosphorylation of NTRK1 at Y674/Y675 induced by TP53-dependent repression of PTPN6 expression: a potential novel prognostic marker for breast cancer.St Gallen 2015 subtyping of luminal breast cancers: impact of different Ki67-based proliferation assessment methods.Low cdc27 and high securin expression predict short survival for breast cancer patients.DCE-MRI Pharmacokinetic-Based Phenotyping of Invasive Ductal Carcinoma: A Radiomic Study for Prediction of Histological Outcomes.Luminal breast cancer classification according to proliferative indices: clinicopathological characteristics and short-term survival analysis.
P2860
Q30576405-3AB7213B-53AE-488E-8506-D936379BCFB0Q30663777-5B5B07CB-206D-4B14-BAC8-E29F3B6390C1Q34023695-A5E622FB-F5C3-4759-ACA0-4FC4194CFE6BQ34466187-4F835F68-867F-4542-ABF7-56BDE040F38FQ34569318-6D7DEEC2-3B1F-457B-8932-E522372E8455Q35347732-9E204D0B-BF20-4CC1-82E5-C30422848B7EQ36040493-6C9BBD43-6A35-4BA0-980F-9CA2EB94F596Q36544839-900DF931-FDC3-4F3D-BA57-550FC51BD64BQ36663651-8FD2F59D-A75E-46EE-BE6F-032FDC8FB569Q36668293-740CB215-B663-4CB3-BF91-B06C2624F8DEQ37086768-EFEC3700-29D7-4550-B761-81A684F4205CQ37316156-A34E05E3-5ECA-4238-9B4C-7D8EC72E7787Q37714123-3F5844AB-F703-4009-81EA-A2FBEFC2AE4EQ38081243-DE9B4532-33F4-4C81-9DEC-EACC5310D001Q38150774-05E11021-C80C-4F78-A430-C78F67144A06Q39022633-F5CE2E19-94ED-4808-A323-0CCB50AA2E97Q41134904-9C8DFED3-758A-4192-93C0-24F3E93B075EQ42362672-8623CDFA-C638-4578-8E54-7E2F4A6A21A9Q45873470-40125693-564A-479F-8E90-0D0497C4C14BQ46209209-444B3CCC-928C-4FB5-AFF1-508524AB8FADQ47205521-B2E4062D-476F-45FE-80AD-5E5C6F5B2CD1Q47772405-0B3C194B-8B5E-449B-88AF-5177E2CC62A7Q48511251-FC2B4C15-ADB9-4356-972A-1294E2EA7A5EQ50918197-9797995C-00AF-4A33-94A4-71B25CC2CB3CQ51734273-B3BC0170-9255-49C7-A0BF-5F4005A1293AQ54344267-BB22B86F-ACCE-4732-8D63-09C5B5644856
P2860
Molecular classification of estrogen receptor-positive/luminal breast cancers.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Molecular classification of estrogen receptor-positive/luminal breast cancers.
@en
Molecular classification of estrogen receptor-positive/luminal breast cancers.
@nl
type
label
Molecular classification of estrogen receptor-positive/luminal breast cancers.
@en
Molecular classification of estrogen receptor-positive/luminal breast cancers.
@nl
prefLabel
Molecular classification of estrogen receptor-positive/luminal breast cancers.
@en
Molecular classification of estrogen receptor-positive/luminal breast cancers.
@nl
P1476
Molecular classification of estrogen receptor-positive/luminal breast cancers.
@en
P2093
Daniel N Rodrigues
Felipe C Geyer
P356
10.1097/PAP.0B013E31823FAFA0
P577
2012-01-01T00:00:00Z